Fierce Biotech June 29, 2022
After years of harnessing AI’s promise, the biopharma industry has recently begun to prove that artificial-intelligence-designed molecules can leapfrog their traditionally developed counterparts on their way toward human testing. These days, drugmakers realize that they can shave months or more off of early research stages by incorporating AI.
It’s the result of decades of work, and it’s happening at a time when computer models are finally gaining access to both the massive amounts of computing power and the enormous data sets necessary to uncover potentially new therapies for hard-to-treat diseases.
But if you had to land on a metaphor for the current level of maturity of this technology, would it be described as a toddler starting to...